309 related articles for article (PubMed ID: 28660408)
21. High Ki-67 index in fine needle aspiration cytology of follicular thyroid tumors is associated with increased risk of carcinoma.
Mu N; Juhlin CC; Tani E; Sofiadis A; Reihnér E; Zedenius J; Larsson C; Nilsson IL
Endocrine; 2018 Aug; 61(2):293-302. PubMed ID: 29796987
[TBL] [Abstract][Full Text] [Related]
22. Thyroid follicular carcinoma: sonographic features of 50 cases.
Sillery JC; Reading CC; Charboneau JW; Henrichsen TL; Hay ID; Mandrekar JN
AJR Am J Roentgenol; 2010 Jan; 194(1):44-54. PubMed ID: 20028904
[TBL] [Abstract][Full Text] [Related]
23. Differential reactivity for galectin-3 in Hürthle cell adenomas and carcinomas.
Nascimento MC; Bisi H; Alves VA; Longatto-Filho A; Kanamura CT; Medeiros-Neto G
Endocr Pathol; 2001; 12(3):275-9. PubMed ID: 11740048
[TBL] [Abstract][Full Text] [Related]
24. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland?
Lassalle S; Hofman V; Ilie M; Bonnetaud C; Puisségur MP; Brest P; Loubatier C; Guevara N; Bordone O; Cardinaud B; Lebrigand K; Rios G; Santini J; Franc B; Mari B; Al Ghuzlan A; Vielh P; Barbry P; Hofman P
Endocr Relat Cancer; 2011 Oct; 18(5):579-94. PubMed ID: 21778212
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA expression profiling is a potential diagnostic tool for thyroid cancer.
Vriens MR; Weng J; Suh I; Huynh N; Guerrero MA; Shen WT; Duh QY; Clark OH; Kebebew E
Cancer; 2012 Jul; 118(13):3426-32. PubMed ID: 22006248
[TBL] [Abstract][Full Text] [Related]
26. Role of GPER1, EGFR and CXCR1 in differentiating between malignant follicular thyroid carcinoma and benign follicular thyroid adenoma.
Zhao L; Zhu XY; Jiang R; Xu M; Wang N; Chen GG; Liu ZM
Int J Clin Exp Pathol; 2015; 8(9):11236-47. PubMed ID: 26617848
[TBL] [Abstract][Full Text] [Related]
27. Defective ciliogenesis in thyroid hürthle cell tumors is associated with increased autophagy.
Lee J; Yi S; Kang YE; Chang JY; Kim JT; Sul HJ; Kim JO; Kim JM; Kim J; Porcelli AM; Kim KS; Shong M
Oncotarget; 2016 Nov; 7(48):79117-79130. PubMed ID: 27816963
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of molecular expression profiles of Hürthle cell tumors of the thyroid gland analyzed via tissue microarrays.
Hoos A; Stojadinovic A; Singh B; Dudas ME; Leung DH; Shaha AR; Shah JP; Brennan MF; Cordon-Cardo C; Ghossein R
Am J Pathol; 2002 Jan; 160(1):175-83. PubMed ID: 11786411
[TBL] [Abstract][Full Text] [Related]
29. Poorly differentiated oncocytic (hürthle cell) follicular carcinoma: an institutional experience.
Bai S; Baloch ZW; Samulski TD; Montone KT; LiVolsi VA
Endocr Pathol; 2015 May; 26(2):164-9. PubMed ID: 25898815
[TBL] [Abstract][Full Text] [Related]
30. High resolution loss of heterozygosity mapping of 17p13 in thyroid cancer: Hurthle cell carcinomas exhibit a small 411-kilobase common region of allelic imbalance, probably containing a novel tumor suppressor gene.
Farrand K; Delahunt B; Wang XL; McIver B; Hay ID; Goellner JR; Eberhardt NL; Grebe SK
J Clin Endocrinol Metab; 2002 Oct; 87(10):4715-21. PubMed ID: 12364463
[TBL] [Abstract][Full Text] [Related]
31. Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors.
Slosar M; Vohra P; Prasad M; Fischer A; Quinlan R; Khan A
Endocr Pathol; 2009; 20(3):149-57. PubMed ID: 19449140
[TBL] [Abstract][Full Text] [Related]
32. Impact of specific patterns on the sensitivity for follicular and Hurthle cell carcinoma in thyroid fine-needle aspiration.
Renshaw AA; Gould EW
Cancer Cytopathol; 2016 Oct; 124(10):729-736. PubMed ID: 27322887
[TBL] [Abstract][Full Text] [Related]
33. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
[TBL] [Abstract][Full Text] [Related]
34. Expression of telomerase genes in thyroid carcinoma.
Hoang-Vu C; Boltze C; Gimm O; Poremba C; Dockhorn-Dworniczak B; Köhrle J; Rath FW; Dralle H
Int J Oncol; 2002 Aug; 21(2):265-72. PubMed ID: 12118320
[TBL] [Abstract][Full Text] [Related]
35. Analysis of Hurthle cell neoplasms of the thyroid by interphase fluorescence in situ hybridization.
Erickson LA; Jalal SM; Goellner JR; Law ME; Harwood A; Jin L; Roche PC; Lloyd RV
Am J Surg Pathol; 2001 Jul; 25(7):911-7. PubMed ID: 11420462
[TBL] [Abstract][Full Text] [Related]
36. Pathologic features, proliferative activity, and cyclin D1 expression in Hurthle cell neoplasms of the thyroid.
Erickson LA; Jin L; Goellner JR; Lohse C; Pankratz VS; Zukerberg LR; Thompson GB; van Heerden JA; Grant CS; Lloyd RV
Mod Pathol; 2000 Feb; 13(2):186-92. PubMed ID: 10697277
[TBL] [Abstract][Full Text] [Related]
37. Metastatic Follicular Thyroid Carcinoma and the Primary Thyroid Gross Examination: Institutional Review of Cases from 1990 to 2015.
Glomski K; Nosé V; Faquin WC; Sadow PM
Endocr Pathol; 2017 Jun; 28(2):177-185. PubMed ID: 28444500
[TBL] [Abstract][Full Text] [Related]
38. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma.
Savin S; Cvejic D; Isic T; Paunovic I; Tatic S; Havelka M
Exp Oncol; 2006 Mar; 28(1):70-4. PubMed ID: 16614712
[TBL] [Abstract][Full Text] [Related]
39. The RET/PTC oncogene is frequently activated in oncocytic thyroid tumors (Hurthle cell adenomas and carcinomas), but not in oncocytic hyperplastic lesions.
Chiappetta G; Toti P; Cetta F; Giuliano A; Pentimalli F; Amendola I; Lazzi S; Monaco M; Mazzuchelli L; Tosi P; Santoro M; Fusco A
J Clin Endocrinol Metab; 2002 Jan; 87(1):364-9. PubMed ID: 11788677
[TBL] [Abstract][Full Text] [Related]
40. Follicular thyroid neoplasm: clinicopathologic features suggesting malignancy.
Heikkilä A; Siironen P; Hagström J; Heiskanen I; Sankila R; Louhimo J; Haglund C; Arola J
APMIS; 2010 Nov; 118(11):846-54. PubMed ID: 20955457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
